Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadakia, Kunal C., Snyder, Claire F., Kidwell, Kelley M., Seewald, Nicholas J., Flockhart, David A., Skaar, Todd C., Desta, Zereunesay, Rae, James M., Otte, Julie L., Carpenter, Janet S., Storniolo, Anna M., Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://www.ncbi.nlm.nih.gov/pubmed/27009936
http://dx.doi.org/10.1634/theoncologist.2015-0349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://www.ncbi.nlm.nih.gov/pubmed/27009936
http://dx.doi.org/10.1634/theoncologist.2015-0349

Ejemplares similares